More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$47.21B
EPS
0.62
P/E ratio
1865.6
Price to sales
6.58
Dividend yield
--
Beta
0.636342
Previous close
$411.29
Today's open
$409.76
Day's range
$407.11 - $413.93
52 week range
$253.95 - $424.73
show more
CEO
John V. Oyler
Employees
11000
Headquarters
Basel,
Exchange
Nasdaq Global Select
Shares outstanding
114226079
Issue type
American Depository Receipt
Healthcare
Biotechnology & Life Sciences
CLL Society and BeOne Medicines Announce Expanded Partnership to Advance Education and Support Across the CLL/SLL Community
NASHVILLE, Tenn. & SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--CLL Society, a leading authority for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) patients, and BeOne Medicines, a global oncology company, today announced an expanded, multi-year partnership focused on strengthening education, engagement, and access to trusted resources across the CLL/SLL community. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “No two individuals with CLL or SLL are the sa.
Business Wire • Nov 17, 2026

BeOne Medicines Q3 Earnings Call Highlights
BeOne Medicines NASDAQ: ONC raised its 2026 revenue and operating income forecasts after third-quarter sales of its cancer drug BRUKINSA topped $1 billion in the United States for the first time.
MarketBeat • Nov 6, 2026

BeOne Medicines AG (ONC) Q3 2026 Earnings Call Transcript
BeOne Medicines AG ( ONC ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Daniel Maller - Vice President of Investor Relations John Oyler - Co-Founder, Executive Chairman & CEO Aaron Rosenberg - Chief Financial Officer Lai Wang Amit Agarwal - Chief Medical Officer of Hematology Mark Lanasa - Senior VP & Chief Medical Officer for Solid Tumors Matthew Shaulis - General Manager of North America Xiaobin Wu Conference Call Participants Jessica Fye - JPMorgan Chase & Co, Research Division Yigal Nochomovitz - Citigroup Inc., Research Division Sean Laaman - Morgan Stanley, Research Division Andrew Berens - Leerink Partners LLC, Research Division Gregory Renza - Truist Securities, Inc., Research Division Yaron Werber - TD Cowen, Research Division Ziyi Chen - Goldman Sachs Group, Inc., Research Division Michael Schmidt - Guggenheim Securities, LLC, Research Division Presentation Operator Good day, everyone. Welcome to BeOne Medicines Q3 2026 Earnings Call webcast.
Seeking Alpha • Nov 5, 2026

BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of 2026. John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said: “Our strong third quarter results and raised full-year guidance reflect continued rapid global growth and leadership in hematology, anchored by our foundational BTK inhibitor BRUKINSA, which drives powerful and sustained respo.
Business Wire • Nov 5, 2026

Compared to Estimates, BeOne Medicines Ltd. - Sponsored ADR (ONC) Q3 Earnings: A Look at Key Metrics
Although the revenue and EPS for BeOne Medicines Ltd. - Sponsored ADR (ONC) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks Investment Research • Nov 5, 2026

Biotech Earnings: Who Won, Who Lost And Who Pulled Off A 'Historic' Launch?
Biotech stocks offered a mixed third-quarter bag on Thursday, with Arcutis reversing and BeOne Medicines surging deeper into its buy zone.
Investors Business Daily • Nov 5, 2026

U.S. FDA Grants Priority Review to BeOne Medicines' BRUKINSA Combination in First-Line Mantle Cell Lymphoma
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE.
Business Wire • Nov 4, 2026

Gear Up for BeOne Medicines Ltd. - Sponsored ADR (ONC) Q3 Earnings: Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for BeOne Medicines Ltd. - Sponsored ADR (ONC), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2026.
Zacks Investment Research • Nov 3, 2026

BeOne Medicines to Present at the Jefferies Global Healthcare Conference
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026, with a fireside chat at 9:30 a.m. GMT. The live webcast of this event can be accessed from the investors section of the Company's website at https://ir.beonemedicines.com. An archived webcast will be available on the Company's website. About BeOne Me.
Business Wire • Nov 3, 2026

New Strong Buy Stocks for November 3rd
HPE, AER, UGP, ONC and BWFG have been added to the Zacks Rank #1 (Strong Buy) List on November 3, 2026.
Zacks Investment Research • Nov 3, 2026

¹ Disclosures

Open an M1 investment account to buy and sell BeOne Medicines Ltd. commission-free¹. Build wealth for the long term using automated trading and transfers.